Spectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet
Spectral AI completed the first Site Initiation Visit for a clinical study supporting label expansion of its FDA-cleared DeepView System to burns of the head, hands, and feet. The SIV was conducted at Pinderfields Hospital in Wakefield, UK under Principal Investigator Dr. Preetha Muthayya, enabling patient enrollment to begin at the first site.
Key figures
- Drug Name
- DeepView System
- Phase Of Trial
- Prospective training and validation label expansion study
- Image dataset
- over 340 billion pixels of burn wound image data
- Imaging window
- within 72 hours of injury
- Outcome assessment
- through 21 days
- Study completion expected
- 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.